2022
DOI: 10.1016/j.pcl.2022.01.012
|View full text |Cite
|
Sign up to set email alerts
|

Analgesia, Sedation, Paralytics, Delirium, and Iatrogenic Withdrawal

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
4
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(4 citation statements)
references
References 37 publications
0
4
0
Order By: Relevance
“…Midazolam, a benzodiazepine, is commonly used in conjunction with an opioid in the management of acute and chronic pain to manage agitation (Ng et al., 2017). Midazolam has also been associated with adverse neurological outcomes and concerns have been raised about its safety and efficacy in the neonatal population (Ng et al., 2017; Valentine & Kummick, 2022). Furthermore, midazolam has no analgesic relieving properties and its use may result in over‐sedation and an inability to accurately assess pain (Valentine & Kummick, 2022).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Midazolam, a benzodiazepine, is commonly used in conjunction with an opioid in the management of acute and chronic pain to manage agitation (Ng et al., 2017). Midazolam has also been associated with adverse neurological outcomes and concerns have been raised about its safety and efficacy in the neonatal population (Ng et al., 2017; Valentine & Kummick, 2022). Furthermore, midazolam has no analgesic relieving properties and its use may result in over‐sedation and an inability to accurately assess pain (Valentine & Kummick, 2022).…”
Section: Discussionmentioning
confidence: 99%
“…Midazolam has also been associated with adverse neurological outcomes and concerns have been raised about its safety and efficacy in the neonatal population (Ng et al., 2017; Valentine & Kummick, 2022). Furthermore, midazolam has no analgesic relieving properties and its use may result in over‐sedation and an inability to accurately assess pain (Valentine & Kummick, 2022). The addition of dexmedetomidine, a highly selective alpha‐2‐adrenergic receptor agonist with both sedative and analgesic properties (Morton et al., 2021), also resulted in additional feedback.…”
Section: Discussionmentioning
confidence: 99%
“…The most used pharmacological analgesia in neonates are paracetamol, opioids and local anesthetics [ 44 , 103 ]. The doses and effects of most frequent drugs used in neonates are summarized in Table 5 [ 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 ].…”
Section: Treatmentmentioning
confidence: 99%
“…Current guidelines promote a pharmacological therapy administered in a stepwise approach, together with regular assessment of pain and sedation scores [ 53 , 109 , 110 , 111 , 112 ].…”
Section: Treatmentmentioning
confidence: 99%